Mayne Pharma Group (HAM:HG6) Debt-to-Equity : 0.07 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Mayne Pharma Group Debt-to-Equity?

Mayne Pharma Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €2.1 Mil. Mayne Pharma Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €20.3 Mil. Mayne Pharma Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €336.2 Mil. Mayne Pharma Group's debt to equity for the quarter that ended in Dec. 2023 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mayne Pharma Group's Debt-to-Equity or its related term are showing as below:

HAM:HG6' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.31 Max: 0.73
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Mayne Pharma Group was 0.73. The lowest was 0.07. And the median was 0.31.

HAM:HG6's Debt-to-Equity is ranked better than
77.1% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HAM:HG6: 0.07

Mayne Pharma Group Debt-to-Equity Historical Data

The historical data trend for Mayne Pharma Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Debt-to-Equity Chart

Mayne Pharma Group Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.37

0.38

0.45

0.73

0.08

Mayne Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.52	0.73	0.10	0.08	0.07

Competitive Comparison of Mayne Pharma Group's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mayne Pharma Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Debt-to-Equity falls into.

Mayne Pharma Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mayne Pharma Group's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8.937	+	20.491)	/	392.963
	=	0.07

Mayne Pharma Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.129	+	20.321)	/	336.217
	=	0.07

Mayne Pharma Group (HAM:HG6) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mayne Pharma Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mayne Pharma Group (HAM:HG6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (HAM:HG6) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MAYNF:USA HG6:Germany MYX:Australia

Address

1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106

Website

http://www.maynepharma.com

Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Mayne Pharma Group (HAM:HG6) Headlines

No Headlines